Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI

niversitätsklinikum Heidelberg0 个研究点目标入组 24 人开始时间: 2020年4月27日最近更新: 2024年8月19日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 24

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized controlled study
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 60 Years（—）
性别: All

入选标准

•1. Age 18-60 y inclusive at the time of consent,
•2. Males and females of child-bearing potential who are willing to use a highly effective method of contraception during the treatment and for 3 months after last administration of the IMP or women not of child-bearing potential (WNCBP) or individuals who are convincingly sexually abstinent.
•3. Understanding, ability, and willingness to fully comply with trial interventions and restrictions,
•4. Willingness to participate in a genotyping study (K093), and
•5. Ability to provide written, personally signed and dated informed consent to participate in the trial, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6, and applicable regulations, prior to any trial-related interventions.

排除标准

•1. Clinically significant or relevant abnormalities in the medical history, physical examination, and laboratory evaluation as assessed by the investigator,
•2. Any medical disorder that may require treatment or make the participant unlikely to fully complete the trial, or any condition that presents undue risk from the IMPs or trial interventions,
•3. Clinically relevant ongoing or clinically relevant history of physical or psychiatric illness as judged by the investigator,
•4. Pregnancy or breast feeding,
•5. Any acute or chronic illness or clinically relevant finding known or expected to modify absorption, distribution, metabolism, or excretion of HCQ, midazolam, yohimbine, or pantoprazole,
•6. Any known history of severe allergic or anaphylactic reactions to drugs or food or any other clinically significant allergies (except mild forms of hay fever),
•7. Any known allergies to the compound or further ingredients of HCQ, quinine, pantoprazole, midazolam, or yohimbine preparations,
•8. Prolonged QTc time: women: QTcF > 460 ms, men: QTcF > 440 MS
•9. Clinically relevant findings at SCR. Minor deviations of laboratory values from the normal range can be acceptable, if judged by the investigator to be of no clinical relevance for this Trial
•10. A positive human immunodeficiency virus and hepatitis C antibody screen,
•11. A positive result in the drug screening test
•12. Any intake of HCQ, chloroquine or travel to malaria risk regions within the last 3 months,
•13. Use of any medication (prescription medication, non-prescription medication including multivitamin or herbal preparations) with active ingredients except hormonal contraception and thyroid hormones, or any intake of substances known to induce or inhibit HCQ-metabolizing enzymes or drug transporters within a period of less than 5 times the respective elimination half-life (t1/2) with regard to the expected date of the first dose of IMP,
•14. Consumption of citrus fruits or products of these fruits within 7 d prior to the expected date of first dose of IMP and expected nonadherence to refrain from such products until V5,
•15. Expected nonadherence to refrain from alcohol 24 h prior to V1 until V5 of this trial, or excessive alcohol consumption.
•16. Intake of quinine, or consumption of quinine-containing drinks (bitter lemon, tonic water, bitter orange)
•17. Use of an IMP within 30 d prior to the expected date of receiving the first dose of IMP or active enrolment in another drug or vaccine clinical trial.
•18. Contraindications to HCQ use

研究者

发起方

niversitätsklinikum Heidelberg

相似试验

已完成

4 期

The effect of routine pantoprazole administration when compared to placebo on gastrointestinal bleeding, ventilator-associated pneumonia and Clostridium difficile infection in enterally-fed mechanically ventilated critically ill patients: A prospective randomised studyCritical IllnessClostridium difficile infectionMetabolic and Endocrine - Other metabolic disordersInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonVentilator-associated PneumoniaGastrointestinal Bleeding

ACTRN12613000807752Dr Adam Deane500

尚未招募

1 期

Study of Pantoprazole in a Patients with Head & Neck Cancers

CTRI/2018/02/011824Tata Memorial Centre

已完成

4 期

The influence of omeprazole and pantoprazole on the platelet reactivity and inhibition of platelet aggregration of clopidogrel.1001108210018027Activity of clopidogrelprophylaxis against NSAID induced gastric damage

NL-OMON32694Atrium Medisch Centrum27

招募中

3 期

The impact of prophylactic pantoprazole dosage on the occurrence of marginal ulcer following one anastomosis gastric bypass surgery in patients with severe obesityMarginal ulcer.Marginal corneal ulcerH16.04

IRCT20190128042520N7Iran University of Medical Sciences120

招募中

不适用

Effects of pantoprazole as an adjunct to standard therapy of uncomplicated amoebic liver abscess.

CTRI/2022/12/048043AIIMS Patna